Abatacept for Treating Rheumatoid Arthritis After the Failure of Conventional Disease-Modifying Anti-Rheumatic Drugs (TA280)

Technology Appraisal Guidance No. 280

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Abatacept in combination with methotrexate is recommended as an option for treating  rheumatoid arthritis in adults whose disease has responded inadequately to 2 conventional  disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate, only if:

  • it is used in accordance with the recommendations for other biological DMARDs in  Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (NICE  technology appraisal guidance 130) and
  • the manufacturer provides abatacept with the discount agreed in the patient access scheme.

1.2 People currently receiving abatacept whose disease does not meet the criteria in section 1.1 should be able to continue treatment until they and their clinician consider it appropriate to stop.

The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at http://guidance.nice.org.uk/TA280

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: nice@nice.org.uk

Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs.

Issue Date: April 2013

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Proposed withdrawal of bipolar disorder treatment revoked

Proposed withdrawal of bipolar disorder treatment revoked

The manufacturer of first-line bipolar disorder treatment...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

NICE recommends further migraine prevention option

NICE recommends further migraine prevention option

Galcanezumab (Emgality) is the second calcitonin gene-related...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...